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Summary
Objective: To examine the chondrogenic activity of AG-041R and its mode of action in a bipotent chondroprogenitor cell line CL-1.
Design: Chondrogenic activity of AG-041R in CL-1 was examined by histology, alcian blue pH 1.0 intensity and mRNA expression of cartilage
matrix proteins (collagen type II, aggrecan). Chondrogenic activities of other CCK2/gastrin receptor antagonists were also examined. Since
TGF-b1 induces dominant chondrogenesis and suppressed adipogenesis in CL-1, induction of TGF-b by AG-041R was examined by enzyme
linked immunosorbent assay. Involvement of MAP kinases in the chondrogenic effect of AG-041R in CL-1 was examined by Western blotting
and MAP kinase inhibitors.
Results: AG-041R induced dominant chondrogenesis and marked suppression of adipogenesis in CL-1. Neither of the other CCK2/gastrin
receptor antagonists tested showed chondrogenic activity in CL-1. AG-041R increased alcian blue pH 1.0 intensity and mRNA expression of
collagen type II and aggrecan. TGF-b1 and -b2 proteins were increased by AG-041R. The chondrogenic activity of AG-041R in CL-1 was
blocked by TGF-b neutralizing antibody or inhibitors for activation of latent TGF-b. AG-041R activated both Erk (p44/42) and p38 MAP kinases
in CL-1. Inhibition of Erk (p44/42) by PD98059 canceled the adipogenesis suppression by AG-041R in CL-1. Inhibition of p38 by SB202190
completely canceled the chondrogenic activity of AG-041R in CL-1.
Conclusion: AG-041R has chondrogenic activity in CL-1 not related to CCK2/gastrin receptor antagonism. It is suggested that TGF-b induction
and the activation of MAP kinases mediate the chondrogenic activity of AG-041R in CL-1.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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It is considered that chondrocytes are derived from multi-
potent mesenchymal stem cells, which also give rise to
muscle, fat and bone1. In recent studies, multipotent
mesenchymal stem cells were isolated from not only fetus2
but also bone marrow of an adult animal3,4. It is suggested
that chondroprogenitor cells have regenerating potency for
articular cartilage injuries in animal models for cartilage
injury5.
We hypothesized that chondroprogenitor cell line derived
from adult animal can be a useful tool for the understanding
of chondrogenesis in adult animal. A bipotent cell line CL-1
which differentiates into chondrocytes and adipocytes was
established from adult mouse. Since chondrogenic growth
factors, including transforming growth factor-b (TGF-b) and
insulin-like growth factor I (IGF-I), stimulate the chondro-
genesis in this cell line, it is suggested that CL-1 can be
a useful tool for the understanding of cartilage regeneration
in adult animals6.
On the other hand, we serendipitously found a chondro-
genic small molecule AG-041R, which is originally synthe-
sized as a CCK2/gastrin receptor antagonist
7. Systemically
administered AG-041R induced systemic cartilage
hyperplasia in rats8. Furthermore, AG-041R shows
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model in rabbits9. These suggest that AG-041R might be
a novel and valuable cartilage-regenerating drug.
Histological ﬁndings, differentiation of chondrocytes from
periosteum and increase of cartilage matrix, suggested that
the target cells of this compound are chondrocytes and
chondroprogenitors in rats8. Actually, AG-041R shows
chondrogenic activities in articular chondrocytes in vitro10,11.
The chondrogenic effect of AG-041R in rat articular
chondrocytes is mediated by endogenous bone morphic
protein-2 and activation of mitogen-activated protein (MAP)
kinases10. However, chondrogenic activity and the mode of
action of AG-041R in chondroprogenitor cells, an important
cellular factor in cartilage regeneration, are still unknown.
To elucidate the mode of action of AG-041R in CL-1, we
examined following points. First, to assess the relationship
between the CCK2/gastrin receptor antagonistic activity
and the chondrogenic effect of AG-041R, chondrogenic
activities of other CCK2/gastrin receptor antagonists
L-365,260R12 or YM-02213 were examined in CL-1 cells.
To clarify the relationship between the structure and the
chondrogenic activity of AG-041R, the chondrogenic activity
of AG-041S, an enantiomer of AG-041R, was also
examined in CL-1. Second, since TGF-b induces dominant
chondrogenesis in CL-1, the involvement of endogenous
TGF-b in the chondrogenic activity of AG-041R in this cell
line was examined. Third, since AG-041R activates MAP
kinases in articular chondrocytes10, activation of MAP
kinases (Erk and p38) was also examined.
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Fig. 2. Chondrogenic effect of AG-041R on chondroprogenitor cell lines. (A, B) Histological change in CL-1 induced by AG-041R. A, control
(0.1% DMSO); B, AG-041R 10 mmol/L. AG-041R induced dominant chondrogenesis and marked suppression of adipogenesis in CL-1.
Treatment for 7 days after conﬂuence. Double staining of alcian blue pH 1.0 and oil red O. Counter-staining: 0.3% nuclear fast red. (C) Alcian
blue intensity was measured after 7 days culture in the presence of AG-041R or vehicle control (0.1% DMSO). AG-041R induced drastic
increase of alcian blue intensity in CL-1. The chondrogenic effect of AG-041R revealed in a dose-dependent manner. *: P! 0.05,
**: P! 0.01: Signiﬁcant difference from control (Student’s t test).
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Fig. 1. Chemical structures of CCK2/gastrin receptor antagonists.
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MATERIALS
CCK2/gastrin receptor antagonists, AG-041R (3-(R)-1
(2,2-diethoxyethyl)-3-((4-methylphenyl)aminocarbonylmethyl)
-3-((4-methylphenyl)ureido)-indoline-2-one)14, AG-041S (3-
(S)-1-(2,2-diethoxyethyl)-3-((4-methylphenyl)aminocarbony-
lmethyl)-3-((4-methylphenyl)ureido)-indoline-2-one, L-365,
260R (3-(R)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,
4-benzodiazepin-3-yl)-N#-(3-methylphenyl)urea)12 and YM-
022 ((R)-1-[2,3-Dihydro-1-(2#-methylphenacyl)-2-oxo-5-
phenyl-1H-1,4-benzodiazepin-3-yl])13 were synthesized by
Chugai Pharmaceutical Co., Ltd. The chemical structures of
these CCK2/gastrin receptor antagonists are shown in Fig. 1.
CHONDROGENIC ACTIVITY OF AG-041R IN CL-1
CL-1 cells were cultivated in a-minimum essential
medium (MEM) (GIBCO, Gland Island, NY, USA) contain-
ing 10% fetal calf serum (FCS) (INTERGEN Purchase, NY,
USA), 100 U/mL penicillin G (Banyu pharmaceutical Co.
Ltd., Tokyo, Japan) and 100 mg/mL streptomycin sulfate
(Meiji Seika Kaisha, Tokyo, Japan) at 37(C in 5% CO2 in
95% humidiﬁed air. Culture medium was changed every 2
or 3 days.
CL-1 cells were cultured in 4-well chamber slides
(5! 103 cells/cm2, Nalge Nunc International, Rochester,
NY, USA) and 24-well plates (5! 103 cells/cm2, CORN-
ING, Corning, NY, USA) in the following treatment. After
conﬂuence, these cell lines were treated with 0.1, 1.0, and
10 mmol/L AG-041R or 0.1% dimethylsulfoxide (DMSO:
a vehicle control, Wako Pure Chemical Industries, Osaka,
Japan). One week after this addition, alcian blue intensity
in the 24-well plates (CORNING) was measured. After
ﬁxation by 4% paraformaldehyde (PFA) (Wako Pure
Chemical Industries) for 1 h, the cell layers were stained
overnight with alcian blue pH 1.0 (Wako Pure Chemical
Industries). After washing with 0.1 mol/L HCl (Wako Pure
Chemical Industries), alcian blue pigment was extracted
with 6 mol/L guanidineeHCl (Wako Pure Chemical
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Fig. 3. The effect of AG-041R on the growth of CL-1. AG-041R
signiﬁcantly suppressed growth of CL-1 cells at the concentration of
0.1e10 mmol/L in a dose-dependent manner similar to TGF-b1.
Control: a-MEM containing 0.1% DMSO and 20% FCS. Medium:
a-MEM containing 20% FCS. MeanC SD values. *: P! 0.05,
**: P! 0.01 (signiﬁcant difference from control, Student’s t test).
##: P! 0.01 (signiﬁcant difference from medium, Student’s t test).Industries). Absorption at 650 nm (alcian blue intensity)
was measured by a spectrophotometer (UV-2200, Shimad-
zu, Tokyo, Japan).
The chamber slides were ﬁxed with 4% PFA (Wako Pure
Chemical Industries), stained with alcian blue pH 1.0 and oil
red O, and counter-stained with 0.3% nuclear fast red
(MERCK, Munich, Germany) for light microscopy.
CHONDROGENIC EFFECTS OF OTHER CCK2/GASTRIN
RECEPTOR ANTAGONISTS ON CL-1
To examine the relationship between the chondrogenic
effect of AG-041R and CCK2/gastrin receptor antagonistic
activity, chondrogenic effects of other CCK2/gastrin re-
ceptor antagonists (L-365,260R, YM-022: 0.1, 1, 10 mmol/L,
AG-041S: 1, 10 mmol/L, 0.1% DMSO: vehicle control) in
CL-1 were compared with that of AG-041R. CL-1 cells were
plated in 24-well plates (5! 103 cells/cm2, BD Biosciences,
San Jose, CA, USA) in a-MEM (GIBCO) containing 10%
FCS (INTERGEN), 100 U/mL penicillin G (Banyu Pharma-
ceutical Co. Ltd.) and 100 mg/mL streptomycin sulfate (Meiji
Seika Kaisha) at 37(C in 5% CO2 in 95% humidiﬁed air.
Culture medium was changed every 2 or 3 days. Chondro-
genesis was measured by alcian blue intensity after 1-week
treatment as described above.
GROWTH OF CL-1
CL-1 cells were plated on ﬂat bottom 96-well plates
(5! 102 cells/well, BD BioSciences) in a-MEM (GIBCO)
day
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Fig. 4. Effect of AG-041R on synthesis of cartilage matrix proteins in
CL-1. Expression of mRNA of cartilage matrix proteins, including
collagen type II and aggrecan, was examined by Northern blotting
in control (0.1% DMSO) or AG-041R (10 mmol/L) treated CL-1 cells
at 1, 3 and 7 days after addition. Messenger RNA of these proteins
was obviously increased by the AG-041R treatment.
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Fig. 5. Chondrogenic effects of other CCK2/gastrin receptor antagonists on CL-1. Chondrogenic effects of gastrin/CCK2 receptor antagonists
L-365,260R, YM-022 or AG-041S in CL-1. At conﬂuence, L-365,260R, YM-022 (0.1, 1.0, 10 mmol/L), AG-041R, AG-041S (1, 10 mmol/L) or
0.1% DMSO (vehicle control) was added into the culture media of CL-1 cells in 24-well plates. Alcian blue intensity was measured after 7 days
culture in the presence of L-365,260R, YM-022, AG-041R, AG-041S or 0.1% DMSO. Neither L-365,260R nor YM-022 signiﬁcantly increased
the alcian blue intensity of CL-1 (upper panels). AG-041S signiﬁcantly suppressed the alcian blue intensity of CL-1 at the concentrations of 1
and 10 mmol/L (lower panel). MeanC SD values. **: P! 0.01 (signiﬁcant difference from control, Student’s t test).containing 20% FCS (INTERGEN). Three days later, AG-
041R (0.1, 1, 10 mmol/L) was supplemented into each well
at the respective dose. a-MEM (GIBCO) containing 20%
FCS (INTERGEN) and 0.1% DMSO (Wako Pure Chemical
Industries) was used as a vehicle control. As positive
controls, TGF-b1 (0.1, 1.0, 10 ng/mL, AUSTRAL BIOLOG-
ICALS, San Ramon, CA, USA) was supplemented into
each well at the respective dose. Twenty-four hours after
the factors were supplemented, cells were labeled with [3H]-
methyl-thymidine (0.1 mCi/well, Amersham, Tokyo, Japan)
for a further 6 h. Each dose was triplicated. DNA was
retrieved on glass ﬁlters (LKB, Bromma, Sweden) and
radioactivity was counted by a scintillation counter (Beta-
plate 1205-012, LKB).
NORTHERN BLOTTING
Total RNA was extracted from CL-1 cells using ISOGEN
(Nippon Gene, Tokyo, Japan). One microgram of total RNA
was separated on 1% agarose/formaldehyde gels, trans-
ferred to nylon membranes (Millipore, Bedford, MA, USA)
and hybridized with either digoxigenin (DIG)-labeled colla-
gen type II or aggrecan RNA probes. After washing, the
blots were probed with alkaline phosphatase conjugated-
anti DIG antibody (Roche Diagnostics, Mannheim, Ger-
many) and chemiluminescent signals were detected usingCSPD (Roche Diagnostics) as the substrate. The blot was
also stained with methylene blue (Wako Pure Chemical
Industries) to show similar loading of RNA.
ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
OF TGF-b1 AND -b2
CL-1 cells were plated in 100-mm plastic dishes (1! 105
cells/dish, BD Biosciences) in triplicate. After conﬂuence,
the cells were cultivated in 10 mmol/L AG-041R or 0.1%
DMSO (Wako Pure Chemical Industries) as a vehicle
control. The culture media were retrieved before (day 0) and
1, 2, 3 and 6 days after the addition for ELISA of TGF-b1
and -b2. After 6 days, the cell layer was retrieved with a cell
scraper (BD Biosciences) and homogenized with a Waring
blender (Iuchi, Tokyo, Japan). The culture media and
supernatants of the homogenized cell layer were used for
ELISA of active form TGF-b1 and -b2 (Emax
 ImmunoAs-
say Systems, Promega, Madison, WI, USA). To measure
the total TGF-b1 and -b2, these samples were activated by
0.02 mol/L HCl (Wako Pure Chemical Industries). TGF-b1
and -b2 contents in the cell layers were normalized by the
DNA contents of the respective samples using a Hoechst
33258 ﬂuorescent dye (FluoReporter Blue Fluorometric
dsDNA, Molecular Probes, Eugene, OR, USA) and ﬂuores-
cent multiplate reader (SPECTRAFLUOR, TECAN Austria
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Fig. 6. Induction of TGF-b proteins in CL-1 by AG-041R. TGF-b concentrations (A, B: TGF-b1; C, D: TGF-b2) in culture media of control (0.1%
DMSO) or AG-041R (10 mmol/L) treated CL-1. (A, C) Concentration of active TGF-b. (B, D) Concentration of total TGF-b. For this assay,
samples were activated by 0.01 mol/L HCl. TGF-b contents (E: TGF-b1; F: TGF-b2) in the cell layer of the control (0.1% DMSO) or AG-041R
(10 mmol/L) treated CL-1. TGF-b contents were normalized with DNA content in cell layer samples. MeanC SD values. *: P! 0.05,
**: P! 0.01 (signiﬁcant difference from control, Student’s t test).GmbH, Salzburg, Austria) at 360/425 nm of excitation/
emission ﬁlters.
BLOCKING OF TGF-b SIGNALING
To block the TGF-b signaling in AG-041R (10 mmol/L)
treated CL-1 cells cultivated in 96-well plates (BD Bioscien-
ces), TGF-b neutralizing antibody MAS-603 (100 mg/mL,
Harlan Sera-Lab, Loughborough, UK) was added. MOPC-
31C (BD Biosciences) was also used as a control antibody.
Proteoglycan synthesis was measured by the following
protocol. CL-1 cells were plated on 96-well plates for liquid
scintillation (1! 103 cells/well, PerkineElmer Life Sciences,
Wellesley, MA, USA). After CL-1 cells reached conﬂuence,
the cells were treated in 10 mmol/L of AG-041R for 24 h.
Then [35S] sulfuric acid (0.1 mCi/well, PerkineElmer Life
Sciences) was added into the wells and cultivated for
a further 24 h. The cell layer was ﬁxed with 4% PFA (Wako
Pure Chemical Industries) containing 0.5% cetylpyridinium
chloride (Sigma, St. Louis, MI, USA) after removal of culture
media. One hundred microliters of liquid scintillator (Opti-
phase supermix, PerkineElmer Life Sciences) was added
to each well and mixed. Radioactivity was counted by
a liquid scintillation counter (1450 Microbeta, PerkineElmer
Life Sciences).
To block the activation of latent TGF-b in AG-041R
(10 mmol/L) treated CL-1 cells following reagents wereadded into the 96-well plates for liquid scintillation (BD
Biosciences). (1) Aprotinin (0.2, 2.0, 20 TIU/mL, Sigma),
a serine protease inhibitor, (2) mannose-6-phosphate (M6P,
10, 100, 1000 mmol/L, Sigma), an inhibitor of IGF-II/M6P
receptor, (3) decanoyl-Arg-Val-Lys-Arg-chrolo-methylketone
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Fig. 7. Blocking of TGF-b signaling by neutralizing antibody in AG-
041R treated CL-1. 100 mg/mL neutralizing antibody MAS-603
almost completely blocked the stimulation of proteoglycan synthesis
by AG-041R. MOPC-31C, a control murine IgG1 did not block the
chondrogenic effect of AG-041R in CL-1. MeanC SD values. ##:
P! 0.01 (signiﬁcant difference from control, Student’s t test).
**: P! 0.01 (signiﬁcant difference from AG-041R, Student’s t test).
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Proteoglycan synthesis was measured with [35S] sulfate
(PerkineElmer Life Sciences) as described.
DETECTION OF MAP KINASE ACTIVATION
Total cell lysates were prepared in the sodium dodecyl
sulfate (SDS) sample buffer from CL-1 cells after incubation
with stimulants for 1, 3, 5, 10, 30, 60, 120 min (for p44/42:
Erk MAP kinase) or 30 min (for p38 MAP kinase). Lysates
were analyzed by SDS-PAGE and transferred to polyviny-
lidene ﬂuoride membranes (Millipore, Billerica, MA, USA).
The blots were probed with anti-Erk mitogen-activated
protein kinase (MAPK), anti-phospho-Erk MAPK, anti-p38
MAPK, and anti-phospho-p38 MAPK antibodies (Cell
Signaling Technologies, Bevery, MA, USA). Horseradish
peroxidase-conjugated anti-rabbit IgG (Cell Signaling Tech-
nologies) was used as a secondary antibody. Chemilumi-
nescent signals were detected using LumiGlo reagents (Cell
Signaling Technologies).
EFFECT OFMAP KINASE INHIBITORSON THE CHONDROGENIC
ACTIVITY OF AG-041R
CL-1 cells were plated on 6-well culture plates (5! 103
cells/cm2, BD Biosciences). At conﬂuence, control (0.1%
DMSO), TGF-b1 (10 ng/mL) or AG-041R (2 mmol/L) was
added to the cultures which were maintained for an
additional week. At the addition of DMSO, TGF-b1 or AG-
041R, PD98059 MEK 1/2 inhibitor (50 mmol/L, Cell Signal-
ing Technologies) or SB202190 p38 MAP kinase inhibitor
(20 mmol/L, CALBIOCHEM, San Diego, CA, USA) was
supplemented. The cell layer was ﬁxed with 4% PFA (Wako
Pure Chemical Industries), stained with alcian blue pH 1.0
(Wako Pure Chemical Industries) and oil red O (Wako Pure
Chemical Industries), and counter-stained with 0.3%
nuclear fast red for light microscopy.
STATISTICAL ANALYSIS
All statistical analyses were performed with SAS (SAS
Institute, Tokyo, Japan). P! 0.05 was recognized as
signiﬁcantly different.
Results
EFFECTS OF AG-041R ON THE GROWTH
AND DIFFERENTIATION OF CL-1
AG-041R induced dominant chondrogenesis and marked
suppression of adipogenesis in CL-1. AG-041R increased
the alcian blue intensity in CL-1 in a dose-dependent
manner (Fig. 2). Histologically, the chondrocytes induced by
AG-041R formed an apparent chondron-like structure,
namely, CL-1 cells became round, and were surrounded
by territorial cartilage matrix that was intensely positive for
alcian blue pH 1.0 (Fig. 2). AG-041R suppressed the growth
of CL-1 cells in the presence of 20% FCS similar to TGF-b1
(Fig. 3). Expression of aggrecan and collagen type II mRNA
in CL-1 cells was evidently increased by AG-041R
compared with the control culture (Fig. 4).
CHONDROGENIC ACTIVITIES OF OTHER CCK2/GASTRIN
RECEPTOR ANTAGONISTS IN CL-1
AG-041R was originally synthesized as a CCK2/gastrin
receptor antagonist, which has a potent activity (KiZ 1.1
nmol/L for CCK2/gastrin receptor
14). To examine therelationship between the chondrogenic activity and CCK2/
gastrin receptor antagonistic activity of this compound,
chondrogenic activities of other CCK2/gastrin receptor
antagonists were examined in CL-1 (Fig. 5). Neither
L-365,260R (KiZ 1.1 nmol/L for CCK2/gastrin receptor
12)
nor YM-022 (KiZ 0.26 nmol/L for CCK2/gastrin receptor
15)
had chondrogenic effect on CL-1 cells in a 3-week culture
after conﬂuence in examined concentrations. AG-041S, an
enantiomer of AG-041R (KiZ 10 nmol/L for CCK2/gastrin
receptor, unpublished data), suppressed the chondrogen-
esis in CL-1 at examined concentrations (Fig. 5).
TGF-b INDUCTION BY AG-041R IN CL-1
AG-041R increased both TGF-b1 and -b2 proteins in CL-1
(Fig. 6). AG-041R mildly increased the concentrations of
TGF-b1 in both active and latent forms in the culture media
of CL-1 cells. Interestingly, although the active TGF-b2 level
was not increased by AG-041R, latent TGF-b2 was strongly
increased by AG-041R in the culture media of CL-1 cells. In
the cell layer, AG-041R drastically increased the contents of
TGF-b1 and -b2 proteins both in the active and latent forms.
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Fig. 8. Effects of inhibitors of TGF-b activation on chondrogenic
effect of AG-041R in CL-1. (A) Inhibition of TGF-b activation in CL-1
by aprotinin, a serine protease inhibitor or M6P, an IGF-II/M6P
receptor antagonist. Aprotinin drastically suppressed the chondro-
genic activity of AG-041R in CL-1 (2 TIU/mL!). M6P did not inhibit
the effect of AG-041R. (B) Inhibition of furin, a prohormone
convertase, by dec-RVKR-cmk. This inhibitor suppressed the
chondrogenic effect of AG-041R (5 mmol/L!). MeanC SD values.
**: P! 0.01 (signiﬁcant difference from AG-041R, Student’s t test)
##: P! 0.01 (signiﬁcant difference from control, Student’s t test).
293Osteoarthritis and Cartilage Vol. 13, No. 4Also in the cell layer, the increase of the TGF-b2 protein
induced by AG-041R was more evident than that of TGF-b1.
BLOCKING OF TGF-b SIGNALING
To assess the contribution of TGF-b in the chondrogenic
activity of AG-041R in CL-1, TGF-b signaling was blocked
by monoclonal antibody MAS-603, which neutralizes
TGF-b1, -b2 and -b3
16. Chondrogenic activity of AG-041R
was intensely inhibited by this antibody (Fig. 7).
TGF-b is secreted as a latent form consisting of TGF-b
and latency-associated peptide (LAP). Dissociation of TGF-b
and LAP is a necessary process in TGF-b signaling17. It is
reported that this activation is mediated by several pro-
teases18 or IGF-II/M6P receptor19. This processwas blocked
by aprotinin, a serine protease inhibitor, or an excessive
concentration of M6P in CL-1. Aprotinin drastically sup-
pressed the chondrogenic activity of AG-041R in CL-1 cells.
On the other hand, M6P did not block the chondrogenic
activity of AG-041R [Fig. 8(A)].
It is reported that furin, a member of the subtilisin-like pro-
protein convertase family, is an authentic converting enzyme
of TGF-b20. The furin activity was blocked by dec-RVKR-cmk
in CL-1. Dec-RVKR-cmk completely inhibited the chondro-
genic activity of AG-041R in CL-1 [Fig. 8(B)].
MAP KINASE ACTIVATION BY AG-041R
The activation of MAP kinases such as Erk (p44/42) or
p38 was reported in chondrogenesis in ATDC5 induced
by growth and differentiation factor-5, a member of theTGF-b superfamily21. The activating effects of AG-041R on
these MAP kinases in CL-1 are shown in Fig. 9. AG-041R
treatment resulted in strong phosphorylation of Erk (p44/42)
MAP kinases within 1 min, and it lasted for 30 min in CL-1.
This indicates that AG-041R strongly activates the MEK/Erk
signaling pathway in CL-1. On the other hand, TGF-b1
treatment resulted in phosphorylation of Erk (p44/42) in CL-
1 within 3 min, but it disappeared at 10 min after addition.
This indicates TGF-b1 also activates the MEK/Erk signaling
pathway in CL-1 in a weaker and shorter manner than that
of AG-041R.
p38MAPkinasewasmildly activated byAG-041R. TGF-b1
did not activate p38 MAP kinase.
The contribution of the activation of these MAP kinases to
the chondrogenic activity of AG-041R in CL-1 was
examined with the speciﬁc inhibitors (Fig. 10). PD98059
was used as an Erk (p44/42) inhibitor due to its MEK 1/2 (a
MAP kinase kinase) inhibition activity. PD98059 induced
adipogenesis in CL-1 by itself. Interestingly, this inhibitor
canceled the suppressive effects of AG-041R on adipo-
genesis in CL-1. However, it did not affect the chondrogenic
activity of AG-041R. On the other hand, p38 MAP kinase
inhibitor SB202190 completely inhibited the chondrogenic
activity of AG-041R in CL-1.
TGF-b1 increased chondrocytes, which were positive for
alcian blue (pH 1.0) and decreased adipocytes, which were
positive for oil red O (Fig. 10). PD98059 enhanced the
chondrogenic effect of TGF-b1 in CL-1. Treatment with this
compound did not affect the adipogenesis suppression
induced by TGF-b1 in CL-1.0
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Fig. 9. Activation of Erk (p44/42) and p38 MAP kinases by AG-041R in CL-1. (A) Erk (p44/42) MAP kinase activation. Erk (p44/42) activation
was examined by Western blotting in CL-1 cells treated with control (0.1% DMSO), AG-041R (10 mmol/L) or TGF-b1(1 ng/mL, 0.1% DMSO) at
1, 3, 5, 10, 30, 60 and 120 min after the addition. Ten percent of FCS in medium was used as a positive control at 5 min after the addition. AG-
041R intensely activated Erk (p44/42) MAP kinase from 1 to 30 min. TGF-b1 activated Erk (p44/42) MAP kinase from 1 to 5 min. All the culture
medium contains 0.1% DMSO. (B) p38 MAP kinase activation. p38 MAP kinase activation was examined at 30 min after AG-041R addition. As
positive control, 0.7 mol/L NaCl was used. AG-041R mildly activated p38 MAP kinase. TGF-b1 did not activate p38 MAP kinase. All the culture
medium contains 0.1% DMSO.
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TGF-b1 in CL-1. Treatment with this compound did not
affect the adipogenesis suppression induced by TGF-b1.
Discussion
Chondrogenic activity of AG-041R was examined in
a mouse bipotent cell line CL-1, which differentiates into
chondrocytes and adipocytes spontaneously. TGF-b1 in-
duces dominant chondrogenesis and suppresses adipo-
genesis in this cell line.
AG-041R strongly induced dominant chondrogenesis and
suppressed adipogenesis in CL-1 in a dose-dependent
manner. AG-041R suppressed the growth of CL-1 cells in
a dose-dependent manner. AG-041R increased the mRNA
expression of cartilage matrix proteins, collagen type II and
aggrecan. These results demonstrated the chondrogenic
activity of AG-041R in CL-1. AG-041R has activities similar
to those of TGF-b1 to the growth and commitment of CL-1
6.
Neither other CCK2/gastrin receptor antagonists,
L-365,260R, YM-022 nor AG-041S showed chondrogenic
activity in CL-1. Furthermore, three major metabolites in rat
(1-(2,2-diethoxyethyl)-3-((4-hydroxymethylphenyl)amino-
carbonylmethyl)-3-((4-methylphenyl)ureido)-indoline-2-one,
1-(2,20- diethoxyethyl)-3-((4-methylphenyl)aminocarbonyl-
methyl)-3-((4-hydroxymethylphenyl)ureido)-indoline-2-one
and 1-(2-oxo-ethyl)-3-((4-methylphenyl)aminocarbonyl-methyl)-3-((4-methylphenyl)ureido-indoline-2-one, also had
no chondrogenic activities in CL-1 (unpublished data).
These data demonstrate that the chondrogenic activity of
AG-041R is intrinsic to its chemical structure, not dependent
on its gastrin/CCK2 antagonistic activity.
AG-041R induced TGF-b1 and TGF-b2 proteins in CL-1
cells. TGF-b neutralizing antibody or inhibitors for latent
TGF-b activation blocked the chondrogenic activity of AG-
041R in CL-1. These demonstrate that the induction of
active TGF-b proteins is one of a necessary step for the
chondrogenic activity of AG-041R in CL-1.
On days 0, 1 and 2, active TGF-b2 levels are detected in
the control culture but not in AG-041R treated cultures,
whereas total TGF-b2 was evidently increased by this
compound. This might suggest that AG-041R induces latent
TGF-b2 in CL-1, but this compound suppresses activation of
latent TGF-b2. Detailed elucidation should be performed.
Messenger RNA expression of TGF-b1 was only slightly
stimulated by 10 mmol/L AG-041R. TGF-b2 and TGF-b3
mRNA expression were not changed by AG-041R in CL-1
(RT-PCR, unpublished data). These might suggest that AG-
041R induces TGF-b1 and -b2 in the posttranscriptional
process of TGF-b protein production in CL-1 as reported in
interleukin-1a-treated T lymphocytes22.
AG-041R activated Erk (p44/42) MAP kinases in CL-1.
Since PD98059 reversed adipogenesis, Erk (p44/42)
activation may be necessary for the adipogenesis suppres-
sion by AG-041R in CL-1. It is reported that Erk (p44/42)medium
0. 2    DMSO
PD98059
(50 µmol/L)
SB202190
(20 µmol/L)
AG-041R
(2 µmol/L)
10 µm 10 µm
10 µm 10 µm 10 µm 10 µm
10 µm10 µm10 µm
TGF -β1
(10 ng/mL)
10 µm
Fig. 10. Effect of MAP kinase inhibitors on the chondrogenic effect of AG-041R in CL-1. In control medium (0.1% DMSO in 10% FCS/a-MEM),
PD98059 simulated adipogenesis in CL-1. SB202190 did not alter either chondrogenesis or adipogenesis. AG-041R (2 mmol/L) increased
alcian blue positive cells and suppressed oil red O positive cells. PD98059 increased alcian blue stainability mildly and oil red O positive cells
in the presence of AG-041R. SB202190 canceled stimulated chondrogenesis by AG-041R with no effect on adipogenesis suppression
induced by AG-041R. TGF-b1 (10 ng/ml) also, increased alcian blue positive cells and suppressed oil red O positive cells. PD98059 enhanced
the chondrogenic effect of TGF-b1. On the other hand, SB202190 canceled the chondrogenic effect of TGF-b1. Neither PD98059 nor SB98059
changed adipogenesis suppression induced by TGF-b1. Alcian blue pH 1.0 and oil red O. One week culture. All the culture medium contains
0.2% DMSO.
295Osteoarthritis and Cartilage Vol. 13, No. 4activation suppresses adipogenesis in 3T3L1 cell line23. On
the other hand, TGF-b1 also activated Erk (p44/42) MAP
kinases in a weaker and shorter manner than that of AG-
041R. However, PD98059 did not affect the adipogenesis
suppression by TGF-b1 in CL-1. This suggests that the
adipogenesis suppression by TGF-b1 will be according to
a different signaling system24 that is different from AG-
041R. Furthermore, PD98059 enhanced the chondrogenic
effect of TGF-b1. Erk (p44/42) might play different roles in
the chondrogenesis induced by TGF-b1 compared with that
of AG-041R in CL-1. Further detailed investigation will be
needed to clarify the molecular mechanisms of this
difference.
AG-041R activated p38 MAP kinase in CL-1. SB202190
(20 mmol/L), a p38 MAP kinase antagonist, inhibited the
chondrogenic activity of AG-041R in CL-1. This suggests
that p38 activation is a necessary process in the chondro-
genic activity of AG-041R in CL-1. Lower dosage
SB202190 (2 mmol/L) partially inhibited the chondrogenic
activity of AG-041R in CL-1 (data not shown). This
demonstrates that complete inhibition of p38 is needed to
block the chondrogenic activity of AG-041R in CL-1. On the
other hand, TGF-b1 did not activate p38 in CL-1 in
examined period. However, p38 inhibition canceled the
chondrogenic effect of TGF-b1 in CL-1. It is reported that
TGF-b1 activates p38 in chondroprogenitors such as
ATDC521 or mesenchymal progenitor cells25. These might
suggest that p38 is a necessary kinase for chondrogenesis in
chondroprogenitors. AG-041R and TGF-b1 have different
potency in the activation of Erk and p38MAPkinases inCL-1.
Further detailed investigation will be needed to clarify the
molecular mechanisms of this difference.
The chondrogenesis in CL-1 was evidently stimulated by
AG-041R, an in vivo effective chondrogenic agent8,9. This
might suggest that CL-1 can be a valuable tool for the
screening of cartilage regenerating agent. This cell line can
be also useful to identify the target molecule of the
chondrogenic activity of AG-041R.
In conclusion, AG-041R stimulates chondrogenesis in
a bipotent chondroprogenitor cell line CL-1 in a manner not
related to the CCK2/gastrin receptor antagonistic activity via
endogenous TGF-b and the activation of MAP kinases.
Since chondroprogenitor cells participate in the regenera-
tion of articular cartilage5, AG-041R might become a valu-
able cartilage-regenerating drug according to its
chondrogenic effect on chondroprogenitor cells. On the
other hand, AG-041R may be a useful chondrogenic agent
in tissue engineering for cartilage regeneration26,27.
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